The Stockholm-based company’s selective cathepsin K inhibitor already holds Orphan Drug Designation in OI, as well as Orphan Drug Designation and Rare Pediatric Disease Designation in Perthes disease. The new designation strengthens the candidate ahead of a planned proof-of-concept study in OI, for which Medivir says the study design is finalized and funding secured.

MIV-711 blocks cathepsin K, the main enzyme osteoclasts use to break down collagen in bone. By curbing excessive bone resorption, the drug aims to restore the balance between bone breakdown and bone formation, and so prevent fractures and skeletal deformities. In an OI animal model, MIV-711 has shown significant, dose-dependent improvements in bone strength, quality, and morphology, and clinical data in osteoarthritis support its ability to counteract bone degradation in humans.

Medivir estimates the market potential for such a treatment at a minimum of USD 2.5 billion.

No approved treatment currently addresses the underlying bone fragility in OI. Medivir estimates the market potential for such a treatment at a minimum of USD 2.5 billion.

A Priority Review Voucher gives the holder priority FDA review of a later marketing application, and it can be sold to other companies. The program was introduced in 2012 and has been extended several times, most recently in February 2026. It now runs until September 30, 2029.

“The FDA’s decision confirms both the significant unmet medical need and the scientific rationale for MIV-711. Children with OI live with recurrent fractures, skeletal deformities, and chronic pain, and there is still no approved treatment that addresses the underlying bone fragility. We believe MIV-711 has the potential to become the first,” says Jens Lindberg, CEO of Medivir.